Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Promising cancer treatments were found, but the manufacturer closed.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.

Pexidartinib often causes liver issues and fatigue, especially in women.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

A man developed alopecia areata after starting cancer treatment with vandetanib.